This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Nossent, J C Articles by Swaak, A J. Search for Related Content PubMed PubMed Citation Articles by Nossent, J C Articles by Swaak, A J. Social Bookmarking                         What's this?

Systemic lupus erythematosus VII: frequency and impact of secondary Sjøgren's syndrome

University Hospital Tromsø, Department of Rheumatology, 9038 Tromsø, Norway

A JG Swaak

Zuiderziekenhuis, Department of Rheumatology, 3075 EA Rotterdam, The Netherlands

Background: The prognosis of patients with systemic lupus erythematosus (SLE) largely depends on the severity of cumulative organ damage during the course of the disease. While Sjùgren's syndrome (SS) predominantly affects exocrine glands, a considerable number of patients develop visceral organ damage. Thus, the occurrence of a secondary SS (2°SS) in SLE patients, may result in more extensive organ damage and thereby adversely affect prognosis.

Patients/Methods: 138 patients meeting the 1982 American College of Rheumatology (ACR) classification criteria for SLE were prospectively studied over a mean period of ninety months. 2°SS was diagnosed according to the 1993 European Study Group criteria and complication rates and prognosis were compared between patients with and without SS.

Results: 27 patients (19%) developed SS after a mean period of 48 months. There was a gradual increase in SS prevalence over time after SLE-onset. 2°SS patients were older (mean age 41 vs 35 years, P = 0.03), had less renal disease (19% vs 38%, P = 0.04), more thrombocytopenia (26% vs 9%, P = 0.05) and similar serological profiles (including anti-SSa) as patients without SS. Overall mortality was lower in patients with SS (4% vs 13.5%, P = 0.01), while lifetable analysis showed improved survival estimates for 2°SS patients with borderline statistical significance (P = 0.06).

Conclusions:2SS develops in about one-fifth of SLE patients in a time-dependent fashion: these patients are older, have less renal involvement and their prognosis is at least as good as for those remaining free of SS.

Key Words: lupus • Sjøgren's syndrome • prognosis

Lupus, Vol. 7, No. 4, 231-234 (1998)
DOI: 10.1191/096120398678920046


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Prabu, T. Marshall, C. Gordon, T. Plant, A. Bawendi, S. Heaton, S. Jobson, D Briggs, and S. J. Bowman Use of patient age and anti-Ro/La antibody status to determine the probability of patients with systemic lupus erythematosus and sicca symptoms fulfilling criteria for secondary Sjogren's syndrome Rheumatology, January 1, 2003; 42(1): 189 - 191. [Full Text] [PDF]

				I-M Gilboe, T K Kvien, T Uhlig, and G Husby Sicca symptoms and secondary Sjogren's syndrome in systemic lupus erythematosus: comparison with rheumatoid arthritis and correlation with disease variables Ann Rheum Dis, December 1, 2001; 60(12): 1103 - 1109. [Abstract] [Full Text] [PDF]

				L. Vila, A. Mayor, A. Valent, M Garc, and S Vila Clinical outcome and predictors of disease evolution in patients with incomplete lupus erythematosus Lupus, February 1, 2000; 9(2): 110 - 115. [Abstract] [PDF]